Catia Marques

Pfizer, Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

266

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Effectiveness of the BNT162b2 XBB.1.5-Adapted Vaccine Against COVID-19 Hospitalization Related to the JN.1 Variant in Europe: A Test-Negative Case-Control Study Using the id.Drive Platform

Number of pages: 37 Posted: 11 Jun 2024
Jennifer Nguyen, Marianna Mitratza, Hannah Volkman, Leonie de Munter, Thao Mai Phuong Tran, Catia Marques, Mustapha Mustapha, Srinivas R. Valluri, Jingyan Yang, Andrés Antón, Irma Casas, Eduardo Conde-Sousa, Laura Drikite, Beate Grüner, Giancarlo Icardi, Gerrit Luit ten Kate, Charlotte Martin, Ainara Mira-Iglesias, PhD. Alejandro Orrico-Sánchez, Susana Otero-Romero Otero-Romero, Gernot Rohde, Daiana Stolz, Luis Jodar, John M. McLaughlin and Kaatje Bollaerts
Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Autonomous University of Barcelona - Hospital Universitari Vall d'Hebron, University Hospital Ulm, P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, University Hospital Ulm, University of Genova - Department of Health Sciences, Ziekenhuis Netwerk Antwerpen (ZNA), Centre Hospitalier Universitaire St-Pierre, FISABIO-Public Health, Universitat Autònoma de Barcelona (UAB), Instituto de Salud Carlos III, Goethe University Frankfurt, Freiburg University, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. and P95 Pharmacovigilance and Epidemiology Services
Downloads 266 (247,969)

Abstract:

Loading...

COVID-19, SARS-CoV-2, COVID-19 vaccination, vaccine effectiveness, BNT162b2, XBB adapted vaccine, JN.1